Lima, Peru.
A Peruvian participant in the eclinical trial of the vaccine against the covid-19 of Chinese laboratory Sinopharm fallergy to pneumonia caused by coronavirus, an event that does not mean at all that the vaccine is ineffectivez, warned those responsible for the investigation on Tuesday.
The Peruvian University Cayetano Heredia (UPCH), in charge of the study in which participated victim, Confirmed this Tuesday the death of the woman without revealing whether he had actually received the vaccine or if so he had been administered one placebo, As is done in this rehearsal class.
The UPCH was attended by 6,000 volunteers to participate in the clinical trial of the vaccine of Sinopharm, to which 2,000 were inoculated with vaccine made with the variant of the virus SARS-CoV-2 from Wuhan, to another 2,000 that of Beijing and another 2,000 were applied to one placebo.
Having received the placebo, the woman developed the infectious picture from covid-19 on a regular basis and it got complicated in the suffer from diabetes and hypertension, two risk factors associated with much of the deaths for this disease in Peru, as indicated by Germán Málaga, principal investigator of the clinical trial.
In case you have received any of the vaccines ainvolved in the study, the infection and posterior of the woman may be due to the effectiveness of these is not 100%, UPCH recalled, something that would be to be confirmed.
MORE THAN ONE SERIOUS WEEK
The university reported that she volunteered diagnosed and treated from the beginning of the disease, then one was processed early hospitalization and later when his state was in worse, had access to a mechanical fan in an intensive care unit (UCI).
The Center for Studies and Research has pointed out that “it received all the indicated attention to treat this disease i yours complications and he was fighting for his life for more than a week, without being able to beat him attack of the same “.
The fatal outcome has been reported to the security committee and the competent authorities to complete the research which clarifies this episode.
The UPCH also noted that all study volunteers are informed that they must continue with the usual preventions to prevent the spread of covid-19, as participants do not know if they have received the vaccine or he placebo.
The clinical trial of the Sinopharm vaccine by the UPCH was suspended by the National Institutes of Health (INS) for almost a week in December after a 64-year-old volunteer developed a series of neurological symptoms, Including weakness in the legs, similar to the syndrome of Guillain Barre.
WAITING FOR FIRST VACCINES
The Peruvian government is waiting to receive the first of the 38 million doses from vaccine of Sinopharm which is committed to acquire in this year 2021.
Although the Executive announced that this first batch of vaccines would arrive in January, apparently will not be so after the public administration has not been able to complete the shipment and has been a group of private companies that have agreed to pay and process the plane which will bring the vaccines.
The one of Sinopharm is a priori is the contract of Peru greater to get vaccines after agreeing to also acquire 14 million doses in the British laboratory AstraZeneca and have secured 13.3 million doses provided by the multilateral initiative COVAX, what added up all should be enough for ainmunizar to all their population.
see: Biden seeks to vaccinate all Americans by the end of August
However, a recent survey revealed that one 48% of Peruvians does not want to receive the vaccine because he thinks it will not be safe, mainly because it has developed so quickly and has shortened the normal time limits for clinical trials.
Peru is currently in the midst of the second wave of covid-19 infections, with its health system collapsing again and the number of deaths accelerating again more and more.
In total register more than a million dand cases symptomatic confirmed, of which nearly 40,000 have died, but reports from regional governments, which do count the cases asymptomatic and suspicious, together they raise the number of cases to more than two million. EFE